Skip to main content
. 2016 Jul 6;7(31):49722–49732. doi: 10.18632/oncotarget.10437

Figure 6. CK2 inhibitor-TBB by restoring Ikaros function induces transcriptionally repressive epigenetic changes at the CRLF2 promoter.

Figure 6

(A) Schematic depiction of the qChIP primers used to analyze epigenetic changes following TBB treatment. Positions of primers used for qChIP are indicated relative to the CRLF2 transcription start site (TSS). (B–C) The qChIP analysis of the distribution of IKZF1 (B) and H3K9me3 (C) at the CRLF2 promoter in Nalm6 cells cultured with or without 50 μM TBB for 2 days. (D) The qChIP data of IKZF1 and H3K9me3 enrichment at the CRLF2 promoter in CEM T-ALL cells cultured with or without TBB. (E) The qChIP data of H3K9me3 enrichment at the CRLF2 promoter in primary ALL cells cultured with or without TBB. Graphed data are presented as mean +/− SEM of triplicates of three independent experiments.